Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Autor: Cleary, James M., Mamon, Harvey J., Szymonifka, Jackie, Bueno, Raphael, Choi, Noah, Donahue, Dean M., Fidias, Panos M., Gaissert, Henning A., Jaklitsch, Michael T., Kulke, Matthew H., Lynch, Thomas P., Mentzer, Steven J., Meyerhardt, Jeffrey A., Swanson, Richard S., Wain, John, Fuchs, Charles S., Enzinger, Peter C.

Background: Patients with locally advanced esophageal cancer who are treated with trimodality therapy have a high recurrence rate. Preclinical evidence suggests that inhibition of cyclooxygenase 2 (COX2) increases the effectiveness of chemoradiation,

Externí odkaz: http://hdl.handle.net/10150/618723
http://arizona.openrepository.com/arizona/handle/10150/618723

Expert Consensus Document on Pulmonary Metastasectomy

Autor: Handy, John R., Bremner, Ross M., Crocenzi, Todd S., Detterbeck, Frank C., Fernando, Hiran C., Fidias, Panos M., Firestone, Scott, Johnstone, Candice A., Lanuti, Michael, Litle, Virginia R., Kesler, Kenneth A., Mitchell, John D., Pass, Harvey I., Ross, Helen J., Varghese, Thomas K.

Publikováno v: In The Annals of Thoracic Surgery February 2019 107(2):631-649

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.

Autor: Cleary JM; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Mamon HJ; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Szymonifka J; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Bueno R; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Choi N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Donahue DM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fidias PM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.; University of Arizona Cancer Center, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA., Gaissert HA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Jaklitsch MT; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Kulke MH; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Lynch TP; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Mentzer SJ; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Meyerhardt JA; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Swanson RS; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Wain J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fuchs CS; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA., Enzinger PC; Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. peter_enzinger@dfci.harvard.edu.

Publikováno v: BMC cancer [BMC Cancer] 2016 Jul 13; Vol. 16, pp. 468. Date of Electronic Publication: 2016 Jul 13.